Andrew Graham, the senior director of industrialization at the Aventis Pasteur vaccine site in Pennsylvania, is the new vice president of development at AlphaVax.
The company announced the appointment on Monday. He will join AlphaVax in August.
AlphaVax is currently expanding its manufacturing capabilities and development efforts. It develops vaccines based on so-called alphaviruses.
Graham is a graduate of McGill University with a degree in biochemistry. He earned a Masters in chemical engineering at the University of Waterloo.
AlphaVax: www.alphavax.com
